Saturday, January 28, 2012

Woman gets life sentence in Md. yoga shop murder (AP)

ROCKVILLE, Md. ? A woman convicted of killing her co-worker at an upscale yoga clothing shop in the Washington suburbs, then spinning an elaborate lie about being attacked by two masked men, was ordered Friday to spend the rest of her life behind bars.

Brittany Norwood choked back tears as she apologized to her family and that of her victim in her first public statements since her arrest in March. A jury in November convicted Norwood of first-degree murder for bludgeoning and stabbing 30-year-old Jayna Murray, a co-worker at the Lululemon Athletica shop in Bethesda. Murray had more than 330 distinct wounds.

The judge was unmoved by Norwood's tears, telling the 29-year-old that her crime "exemplified the worst of human nature." He stoutly rejected defense pleas that she was capable of rehabilitation and deserved an eventual shot at freedom.

"You mutilated this woman. And with every blow, you had a chance to think about what you were doing," said Montgomery County Circuit Court Judge Robert Greenberg in imposing a sentence of life without the possibility parole.

The violent nature of the crime, and the initial accounts by Norwood of two murderers and rapists on the run, rattled the community.

Prosecutors said Norwood attacked Murray with at least five weapons, including a knife and a hammer, during a fight March 11 after they closed the shop for the day. They said Norwood lured Murray back to the store by falsely claiming that she has forgotten something inside and needed to be let back in. Norwood savagely beat Murray for at least 20 minutes and then doctored the scene overnight to support her story that intruders had attacked and sexually assaulted them.

Murray was found the next morning in a pool of blood at the back of the store. Her wounds included a knife strike to the head that served as the death blow. Norwood was found nearby, moaning in apparent pain and tied up, with superficial ? and self-imposed ? wounds on her body. Blood was found tracked throughout the store, something police later determined was part of Norwood's attempt to throw them off her trail

The jury didn't hear a motive for the killing, but prosecutor John McCarthy said Murray had confronted Norwood after finding a pair of stolen pants while checking her bag. Norwood feared the discovery would cause her to be fired and derail her planned career as a personal trainer.

"It was more than a pair of pants," McCarthy said. "It was the unraveling of a life that she had set for herself."

Norwood, wiping away tears and speaking softly as a row of family members sobbed, briefly apologized, saying "My hope for your family is that someday you'll be able to find forgiveness in your heart."

Norwood's account of the attack set off panic in Bethesda, an affluent suburb where violent crime is rare. Montgomery County police went on a manhunt and fielded hundreds of tips. Some residents and shoppers who frequented the bustling corridor of high-end shops and trendy restaurants where Lululemon is situated admitted to feeling anxious at night.

"Businesses operated differently," McCarthy said.

Norwood stared to the ground as eight of Murray's friends and family detailed how their once joyful lives have become overcome with nightmares, anxiety, depression and feelings of emptiness. Her father, David Murray, showed the courtroom a series of photographs ? his daughter as a smiling young girl, shooting a bow and arrow, bungee jumping, posing alongside a trophy and in her cap and gown. He said they illustrated his daughter's zest for life and talents as a student, swimmer, dancer and gymnast.

"March 11, 2011 was our family's Sept. 11, 2001," Murray's brother, Hugh, told the judge. "Nothing will ever return to normal. Nothing will ever be the same."

Murray's other brother, Dirk, said his two young sons adored their aunt but were starting to ask difficult questions about her death. When they go to bed at night, he said, the family doesn't check the closets for an anonymous bogeyman. "We check for Brittany Norwood," he said.

The family described how their initial empathy for Murray's surviving co-worker turned ? her father said he even contemplated sending Norwood flowers at the hospital ? transformed into horror and rage when they learned that Norwood was the attacker, not the victim.

"Of the many stages of grief, I have not moved away from rage," David Murray said.

Norwood's tale unraveled within days as police identified her as their sole suspect. Workers at an adjacent Apple store told police that they heard two women ? though they were castigated by the judge Friday for failing to call for help. Investigators found only two sets of footprints in the store. An examination did not back up Norwood's claim of being sexually assaulted. And Norwood's DNA was found inside Murray's car, which Norwood had driven away from the store as part of her ruse.

She was arrested a week after the murder.

Norwood's lawyers conceded at the outset of the trial that Norwood had killed Murray, but said she had simply "lost it" in a moment of irrationality and didn't have the required forethought to be convicted of first-degree murder. A jury rejected that argument after about an hour of deliberation.

Her attorney, Doug Wood, urged a judge to grant her the possibility of parole, though he acknowledged that there was a minimal chance of her ever being granted it. Giving her and her family at least a glimmer of hope is part of the community's collective healing, Wood argued.

A sentence of life without parole, he argued, "forecloses hope. It forecloses redemption. It forecloses forgiveness. It allows anger, hatred and fear to win out."

Source: http://us.rd.yahoo.com/dailynews/rss/crime/*http%3A//news.yahoo.com/s/ap/20120127/ap_on_re_us/us_yoga_shop_killing

cardinals jennifer nicole lee jennifer nicole lee chris harris peter schiff matt holliday project runway winner

Friday, January 27, 2012

Caterpillar 4Q profit rises, tops Wall St. view (AP)

NEW YORK ? Caterpillar Inc. said Thursday that its fourth-quarter profit jumped 60 percent, boosted by pent-up demand for new equipment and continuing growth in developing countries.

The performance of the world's largest maker of construction and mining equipment is an indicator of the strength of the global economy. Along with strong fourth-quarter earnings, Caterpillar issued rosy guidance, saying that it expects the global economy to grow faster this year and construction activity to continue to improve in most parts of the world.

Caterpillar, based in Peoria, Ill., reported net income of $1.55 billion, or $2.32 per share, up from $968 million, or $1.47 per share, in the same quarter last year.

Sales and revenue jumped 35 percent to $17.24 billion, as sales volume increased at all three of the company's major businesses. Revenue from mining equipment company Bucyrus International Inc., which Caterpillar acquired in July, totaled $1.39 billion.

Caterpillar's results easily topped Wall Street predictions for profit of $1.76 per share and $15.95 billion in revenue, according to FactSet. That sent its shares higher and made it one of the biggest gainers in the Dow Jones industrial average on Thursday. The stock rose $2.17, or 2 percent, to $111.22 in heavy afternoon trading, after hitting $114 earlier in the day, within a few dollars of its 52-week high of $116.55.

Caterpillar said that despite the ongoing downturn in the construction industry, many of its customers had to replace their aging equipment during the quarter. In addition, the company continued to get a boost from rapid economic growth in developing parts of the world.

Construction sales rose 31 percent to $5.26 billion, while resource industries sales, which include Bucyrus, jumped 80 percent to $5.06 billion. Sales of power systems were up 22 percent to $5.67 billion.

Caterpillar expects the global economy to grow about 3.3 percent this year, with the U.S. economy expanding by at least 3 percent. In addition U.S. construction spending, which has been declining since 2004, should finally begin to recover, the company said.

But Caterpillar warned that even with the slight recovery, construction spending will remain depressed. And while Europe's economic crisis probably won't trigger a global recession, economic growth in eurozone counties is unlikely to improve until the second half of this year.

Edward Rapp, Caterpillar's chief financial officer, said that despite the ongoing financial crisis in Europe, the company still stands to benefit from projects there.

"It just depends on how much longer this chaos in southern Europe goes on," Rapp said in a conference call with analysts. "It's been going on a long time and hasn't tanked the place yet. We don't think it will."

Caterpillar sees China's economy growing by 8.5 percent in 2012, with more construction and rising demand for commodities bringing more machine sales.

Caterpillar estimates its 2012 profit will be $9.25 per share with $68 billion to $72 billion in revenue. The outlook includes about $6 billion in revenue from Bucyrus and from Motoren-Werke Mannheim Holding GmbH, which Caterpillar also bought last year. Analysts polled by FactSet expect profit of $9.07 per share on $66.99 billion in revenue for Caterpillar this year.

The company said sales of new machines and equipment will continue to improve as customers in developed counties rebuild their fleets. Low interest rates and the expected increase in construction activity are also expected to boost demand.

Caterpillar noted that production of some of its products will be limited by its current capacity to make them, though it added that it's making investments to expand capacity.

In addition, the company expects demand for its mining equipment to continue to be strong globally, as companies around the world increase production.

Morgan Stanley analyst Vance Edelson backed his "Overweight" rating for Caterpillar stock. He said that the company is unique, because it's poised to do well if the economy improves but will remain more stable than expected, if things take a turn for the worse.

"We believe there is upside potential to the implied earnings per share figure," Edelson wrote in a note to investors. "We also note the record sales expectations despite still lackluster construction activity in the U.S. and Europe."

For the full year 2011, Caterpillar earned $4.93 billion, or $7.40 per share, up from $2.7 billion, or $4.15 per share, in 2010. Sales and revenue increased to $60.14 billion from $42.59 billion.

Excluding Bucyrus, Caterpillar earned $7.79 per share and posted $57.61 billion in sales.

Source: http://us.rd.yahoo.com/dailynews/rss/earnings/*http%3A//news.yahoo.com/s/ap/20120126/ap_on_bi_ge/us_earns_caterpillar

50 50 gene simmons family jewels dream house dream house taylor martinez taylor martinez o brother where art thou

Dana White calls out Internet hackers, they respond by releasing his alleged personal info

CHICAGO -- The war is on between the UFC and Internet hackers.

On Sunday, UFC.com was re-routed several times to the website UGnazi. The site's organizers, who White called terrorists several times during the "UFC on Fox 2" press conference, said the hacking of UFC.com is a result of the company's support of SOPA and PIPA. The wide-ranging bills are aimed at stopping online piracy.

White lashed out at the hackers.

Update: White dug in deeper during a conversation with The Score's Mauro Ranallo (13:30 mark).

"Keep hacking our site, do it again. Do it tonight," said White. "These guys look like terrorists now and a bill that was about to die, is about to come back."

The hacker taking credit for the UFC hit, @joshthgod, went a different route after the challenge, posting White's personal info, including a Social Security number, a list of residential addresses, a vehicle identification number and a personal phone number.

That followed a tweet that said White is now the target.

"@danawhite We don't want your site anymore. We are going after YOU! Follow me for tonights exciting events! #ufc #sopa #acta #pipa,"

[Related: Why SOPA, PIPA aren't answer to MMA's piracy problem]

White said the hackers are only hurting their own cause by alerting politicians that there's a serious issue. He's willing to risk his own safety to stop the online pilfering.

"Is SOPA the perfect bill? No, it's not. The only thing that we're focused on is piracy. Piracy is stealing. If you walk into a store and you steal a gold watch, it's the same as stealing a pay-per-view. I don't care what your twisted, demented idea of stealing is," White said. "These kids who grew up on the Internet never had to pay for anything, so they don't think that you should have to."

White closed by saying he's not afraid of the Internet, it's where cowards live.

Other popular content on the Yahoo! network:
? ThePostGame: George Clooney's bewildering Olympic ticket dilemma
? Wetzel: Rob Lowe's tweet sparks feud between Peyton Manning and Colts owner
? Video: NFL's breakout stars set to shine in Pro Bowl
? Work + Money: Why one parent should stay at home

Source: http://sports.yahoo.com/blogs/mma-cagewriter/dana-white-calls-internet-hackers-respond-releasing-personal-142312772.html

espn magazine anywhere but here wall street protesters att new york yankees pittsburgh penguins westboro baptist church

Bristol-Myers reports rise in 4th-quarter profit (AP)

NEW YORK ? Bristol-Myers Squibb Co. reported a 76 percent increase in the fourth-quarter profit Thursday, driven in part by sales of a recently-approved diabetes drug and hefty charges a year earlier, though the drugmaker still fell short of Wall Street's expectations.

The company focused attention on rapid sales growth for its three-year-old oral diabetes drug Onglyza, which increased 110 percent to $153 million. But results were dominated by two established products, blood thinner Plavix and the psychiatric drug Abilify.

Net income rose to $852 million, or 50 cents per share, up from $483 million, or 28 cents per share, in the 2010 quarter.

The New York company said fees and discounts under the U.S. health care overhaul reduced earnings per share by 4 cents in the latest quarter. The year-earlier results were weighted down by $324 million in expenses, including charges for streamlining global operations, depreciation and shutdown costs, licensing payments and a tax charge.

Adjusted income rose 12 percent to $906 million, or 53 cents per share, from $807 million, or 47 cents per share, for the same period of 2010. Total sales increased 7 percent to $5.45 billion from $5.11 billion.

Those results were slightly short of analyst expectations as polled by FactSet, which called for 55 cents per share on sales of $5.51 billion.

"Investors weren't expecting much and they didn't get much," said Erik Gordon an analyst and professor at the University of Michigan's Ross School of Business. "A couple of products beat their sales estimates by a hair and a couple missed by a hair."

Bristol-Myers said it expects 2012 full-year earnings per share between $1.90 and $2.00. Analysts are looking for $1.98 per share, on average.

Company shares fell 22 cents to close at $32.48 Friday.

Bristol-Myers and French partner Sanofi SA jointly market Plavix, the world's second-best-selling drug, which posted a 3 percent drop in sales to $1.67 billion. The drug loses U.S. patent protection in May and Bristol has initiated a dozen or more partnerships and deals aimed at developing new revenue-generating products.

Among the most highly anticipated of those drugs is the anti-clotting pill Eliquis, which is approved in the European Union for preventing clots in patients getting hip or knee replacement surgery. Bristol and its partner on the drug, Pfizer Inc., are seeking U.S. approval for the drug for stroke prevention, which would allow them to market it for millions more patients. The Food and Drug Administration has given Eliquis a priority review, with a March 28 target date for a ruling.

Also scheduled to lose patent protection in the coming year is the blood pressure drug Avapro. Sales of that drug and its foreign counterpart Avalide fell 23 percent, to $195 million. That's because they have generic competition in Canada, a rival's similar drug has generic competition in many countries, and one of the three dosage forms isn't available due to a recall.

Sales of the company's second biggest product, schizophrenia and bipolar drug Abilify, rose 4 percent to $737 million.

For full-year 2011 the company earned $3.71 billion, or $2.16 per share, on sales of $21.24 billion. Excluding one-time items income was $2.28 per share.

Source: http://us.rd.yahoo.com/dailynews/rss/earnings/*http%3A//news.yahoo.com/s/ap/20120126/ap_on_bi_ge/us_earns_bristol_myers

bubba smith bubba smith oakland strike new gmail new gmail oakland general strike oakland general strike

Gingrich unloads on Romney, ads, in Florida speech (AP)

MOUNT DORA, Fla. ? Newt Gingrich on Thursday dramatically ramped up his attacks on Mitt Romney, saying the former Massachusetts governor is guilty of lies, desperation and hypocrisy that should make "every American angry."

Gingrich, the former House speaker, said he was infuriated by a barrage of attack ads that are blistering him on Florida TV stations ahead of Tuesday's GOP presidential primary. Most are funded by an outside organization backing Romney, but some are from Romney's own campaign. Unable to match Romney's money machine, Gingrich implored Florida Republicans to punish his chief rival for what Gingrich called callously dishonest ads.

"This is the desperate last stand of the old order," Gingrich told an outdoor crowd of more than 1,000 northwest of Orlando. "This is the kind of gall they have to think we're so stupid and we're so timid."

The nature and volume of the attack ads are similar to those that badly damaged Gingrich in Iowa a month ago.

"I think all the weight of his negative advertising and all the weight of his dishonesty has hurt us some," Gingrich said. But "I am not going to allow the moneyed interests that are buying those ads to come in here and to come into other states to misinform people and then to think we are too dumb to fight back."

Romney steered clear of his rival during a subsequent campaign appearance.

Gingrich later told reporters he decided to sharpen his criticisms after Romney's tax returns showed investments held in Cayman Island accounts, the government-backed mortgage company Freddie Mac and other entities.

"Here's a guy who owns Freddie Mac and Fannie Mae stock," Gingrich said. "He owns a Goldman Sachs subsidiary, which is foreclosing on Floridians. And on that front he decides to lie about my career? There's something about the hypocrisy that should make every American angry."

Romney has been hammering Gingrich for consulting work he performed for Freddie Mac and telling Florida voters that Gingrich was paid by a company that contributed to the state's poor housing market.

The acerbic remarks came three days after Gingrich took a much more moderate tone in a televised debate in Tampa, when Romney sharpened his own attacks. Gingrich strongly hinted he will be more aggressive in a CNN debate scheduled for Thursday night in Jacksonville.

Romney, meanwhile, toured a Jacksonville factory that is closing because of the economy before he addressed several hundred people gathered outside. He acknowledged that the live audience at Thursday's debate may be fairly raucous, a dynamic that seems to favor Gingrich and his populist, us-against-the-media and us-against-the-establishment style.

"There may be some give and take," Romney said. "That's always fun and entertaining, I know. If you all could get there, we'd love to see you all there cheering."

In his remarks, Romney criticized President Barack Obama and steered clear of Gingrich. He called Obama's administration a "Groundhog Day" presidency in which nothing gets better.

Polls suggest the Florida primary is close, coming 10 days after Gingrich beat Romney by 12 percentage points in South Carolina. Asked if he felt Florida was slipping toward Romney, Gingrich said, "I feel that it's useful for people to look at the totality of his record and ask yourself, `How can a guy who literally owns stock in a Goldman Sachs investment fund that forecloses on Floridians run the ads he's been running?'"

Goldman Sachs employees and their families contributed $367,200 to Romney's campaign through Sept. 30, his largest source of campaign contributions, according to the Center for Responsive Politics.

Former Pennsylvania Sen. Rick Santorum and Texas Rep. Ron Paul also were participating in Thursday's debate, the final one before the GOP presidential primary in Florida on Tuesday. But both candidates have set their sights elsewhere and have largely stayed away from the Romney-Gingrich drama.

Whoever wins Florida will score something no one has yet claimed in a tumultuous primary season: a second victory. The first three contests have been won by three different candidates. Only Paul has yet to score a win.

The hits for Romney and Gingrich were coming from many directions.

The "super" political action committees backing them have spent more than $10 million combined on ads to date in Florida, far more than their respective campaigns. The Romney-leaning Restore Our Future has spent $8.8 million in ads as of late Tuesday, bringing to $14 million the total spent on ads supporting Romney in the state. That doesn't include money already spent on radio and Internet advertising.

As of late Tuesday, the Gingrich-backing Winning Our Future had booked $1.8 million in television ads in Florida, a check made possible by a new donation from Miriam Adelson. She and her husband, Sheldon, this month gave $5 million apiece to the group, which supports Gingrich but legally must remain independent.

Santorum, meanwhile, seemed to be recognizing that he stood almost no chance of winning Florida. He and his advisers planned no advertising in the state and instead were focused on raising money and calling potential supporters in upcoming states. He all but gave up trying to woo a network of pastors and was scaling back his schedule in Florida.

Chuck Laudner, an influential adviser who helped Santorum score an upset victory in the Iowa caucuses, was returning to the Midwest to start piecing together coalitions in Missouri and Minnesota. Both states have media markets that overlap with Iowa, where Santorum proved to be the big story.

Paul, virtually absent from Florida except for appearances built around the debates, was concentrating instead on caucus states where his loyal backers can carry a louder voice.

___

Associated Press writers Charles Babington, Philip Elliott, Kasie Hunt and David Espo in Florida contributed to this report. Jack Gillum contributed from Washington.

Source: http://us.rd.yahoo.com/dailynews/rss/topstories/*http%3A//news.yahoo.com/s/ap/20120126/ap_on_el_pr/us_gop_campaign

sound of music ihop green bean casserole the temptations prime rib recipe norad santa tracker vince carter

Thursday, January 26, 2012

Art Brodsky: PIPA And SOPA Were Stopped, But The Web Hasn't Won (Huffington post)

Share With Friends: Share on FacebookTweet ThisPost to Google-BuzzSend on GmailPost to Linked-InSubscribe to This Feed | Rss To Twitter | Politics - Top Stories News, RSS Feeds and Widgets via Feedzilla.

Source: http://news.feedzilla.com/en_us/stories/politics/top-stories/191372605?client_source=feed&format=rss

one republic carlos santana michael dyer suspended new years rockin eve new years ball drop new york times square jaws

Pharma's niche focus spurs US aid for antibiotics (AP)

WASHINGTON ? The pharmaceutical industry won approval to market a record number of new drugs for rare diseases last year, as a combination of scientific innovation and business opportunity spurred new treatments for diseases long-ignored by drug companies.

Drug companies are increasingly taking advantage of the commercial benefits of developing so-called orphan drugs, which include extra patent protections, higher pricing and a streamlined review process by FDA. Among the innovative treatments approved in the past year were the first new drug for lupus in 50 years and the first new drug for Hodgkin's lymphoma in 30 years.

But the focus on specialty drugs has put pressure on the U.S. government to ramp up its own spending on vaccines, antibiotics and drugs for more widespread health threats, which are less profitable for companies.

Since 2006, government spending on research for familiar diseases like staph infections, smallpox and botulism has increased more than 660 percent, from $54 million to $415 million last year

"Many of these are everyday, general diseases that we thought we had conquered decades ago, but we've seen some of them pop up again," said Dr. Robin Robinson, director of the Biomedical Advanced Research and Development Authority, which is tasked with acquiring vaccines, drugs and other necessities for public health emergencies.

Since 2005, BARDA has awarded $3.5 billion to outside companies to encourage research and production of antibiotics, flu vaccines and other products that are seen as less profitable than specialty drugs.

"We have pushed the envelope more toward diminishing the risk for companies so that they'll be more interested in getting involved with us and developing things like vaccines and antivirals," said Dr. Anthony Fauci, infectious diseases chief at the National Institutes of Health, which funds research into bird flu, tuberculosis and other potential pandemics. The government's role in developing new therapies goes beyond awarding contracts and includes offering assistance in designing trials and recruiting test subjects.

The need for such assistance stems in part from a new focus among pharmaceutical companies on drugs for rare diseases or unusual strains of common diseases.

Eleven of the 30 new drugs approved last year, or 37 percent, were for rare medical conditions, the highest percentage on record since the FDA began offering incentives to develop such therapies, known as orphan drugs, about 30 years ago. Additionally, nearly half of the 30 drugs were cleared under FDA's "fast track" program reserved for drugs that fill an unmet medical need.

"The companies are saying `this is actually a viable model.' Whereas back in the nineties they were skeptical, now they seem convinced," said Mark Schoenebaum, an analyst with International Strategy & Investment.

Analysts credit scientific advances and looming patent expirations with the spate of innovative products. Drugs worth a mammoth $255 billion in global annual sales are set to go off patent before 2016, according to EvaluatePharma Ltd., a London research firm.

The pharmaceutical industry reached its peak of profitability in the 1990s with heavily marketed drugs for common afflictions, like AstraZeneca PLC's Nexium pill for heart burn and Pfizer Inc.'s Lipitor for high cholesterol. In the last decade drugmakers managed to extend the patents on those drugs by tweaking their formulations, resulting in so-called `follow-on' drugs. But with most of those products on the cusp of losing patent protection, drugmakers have finally been forced to innovate, often turning to hard-to-treat diseases for which there are few existing therapies.

The FDA grants companies seven years of exclusive, competition-free marketing for each newly approved orphan drug, as well as tax breaks on the costs of developing the drugs. Orphan drugs also typically command much higher prices than other drugs. Last year French drugmaker Sanofi paid $20 billion to acquire specialty drugmaker Genzyme, whose products range from $100,000 to $300,000 for one year's supply.

One side effect of the focus on developing drugs for rare diseases is increased investment by the government to spur research into more common public health threats with the potential to cause mass outbreaks of illness. One such threat comes from so-called superbugs, or bacteria that have grown resistant to antibiotic drugs.

Robinson says government support is needed to spur antibiotic development because of how sparingly the products are used in medical practice. After decades of routine use, many first-generation antibiotics like penicillin are no longer effective against common bacterial strains, such as the staphylococcus aureaus, which causes staph infections. Physicians are encouraged to use newer antibiotics only in critical situations so that superbugs have less chance to build a resistance to them. As a result, drugmakers do not see a large commercial market for new antibiotics. Now the federal government is providing an incentive.

BARDA has awarded a series of contracts to encourage development of new antibiotics that can be stockpiled for use in a natural outbreak or during a bioterrorism attack.

? The agency has allocated up to $64 million to Achaogen, a San Francisco startup, for development of a new antibiotic against tularemia, a bacterium that can cause pneumonia and urinary tract infections. Public health officials are especially focused on Tularemia because it could also be used in a potential bioterrorism attack. Robinson says the contract is an example a new strategy of encouraging companies to produce therapies with dual uses: as federal preparatory measures and as commercial medical products.

Achaogen has received $155 million in research contracts and has several antibiotics in early and mid-stage, though none are currently available for sale.

? Under a $38.5 million contract awarded in September, BARDA will help GlaxoSmithKline PLC test an experimental antibiotic against both bioterrorism agents and infections like hospital-acquired pneumonia.

The U.S. government has used a similar pump priming strategy to encourage investment in flu vaccines. The Department of Health and Human Services wants to be able to provide enough vaccine for the entire U.S. population within six months of a flu pandemic. To meet that goal the government has tried to boost vaccine production by encouraging more Americans to get the standard flu vaccine each year. The government's hope is that by making the shots routine for more Americans, companies will invest in larger vaccine facilities that can ramp up production in the event of a pandemic.

Last month Swiss drugmaker Novartis AG opened the first U.S. vaccine facility equipped with cell culture technology, a faster method for producing vaccines than the traditional technique using chicken eggs. The U.S. government provided half of the $1 billion investment for the facility, as part of its preparations for a potential flu pandemic.

Source: http://us.rd.yahoo.com/dailynews/rss/health/*http%3A//news.yahoo.com/s/ap/20120125/ap_on_he_me/us_dread_disease_aid

meet the press barry sanders barry sanders jay z chris herren pierre thomas beyonce gives birth